Last update 31 May 2025

TransCon IL-2 beta/gamma(Ascendis Pharma)

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Onvapegleukin alfa, TransCon IL-2 β/γ - Ascendis Pharma
Target
Action
agonists
Mechanism
IL-2R agonists(Interleukin-2 receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
United States
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
Georgia
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
Germany
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
Hungary
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
Italy
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
Poland
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
Spain
29 Sep 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 2
Taiwan Province
29 Sep 2023
Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 2
United States
29 Sep 2023
Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 2
Georgia
29 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Platinum-Resistant Ovarian Carcinoma
cytotoxic lymphocytes (CLs)
12
TransCon IL-2 β/γ + Pemetrexed
tlymvwfqeu(oqkvwzzhqd) = 66.7% kiaixzsuiy (muwuqvfjop )
Positive
14 Sep 2024
Phase 1/2
-
aijhyimtnx(cceupwvqwe) = tzznloaptu lclbqtnwqa (ihalybmgja )
Positive
03 Jun 2024
(colorectal cancer)
eycsfgnrha(duxoczohkp) = ltlkjswmst gwageecagg (ymsfjkzing )
Phase 1/2
Solid tumor
absolute lymphocyte counts (ALC) | cytotoxic lymphocytes (CLs) | soluble CD25 ...
46
mrophkspgu(qbmmtlnwiz) = eujmruvdwc qlzxhceknm (pnnchmsmcx )
Positive
24 May 2024
mrophkspgu(qbmmtlnwiz) = zwbkkmrxmt qlzxhceknm (pnnchmsmcx )
Phase 1/2
39
TransCon IL-2 β/γ (20 to 160 mcg/kg)
cqnfhufagf(jjqjqzatar) = azyatfasqq xhqxpnhhqr (ovsdmlxury )
Positive
23 Oct 2023
cqnfhufagf(jjqjqzatar) = avffbhelqk xhqxpnhhqr (ovsdmlxury )
Phase 1/2
27
jejyvwcmob(gbnaspaeaw) = 1 Dose Limiting Toxicity of G3 CRS was reported at DL4. vreqiqvncu (nhiczxjbdt )
Positive
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free